Company / Total Assets
Vertex Pharmaceuticals Total Assets History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Total Assets
$25.6B
FY2025
5-year range
$13.4B / $25.6B
FY2021-FY2025
Trend
+13.8%
vs FY2024
Sector context
#15 of 214
Health Care
What the data says
Among 214 Health Care companies, Vertex Pharmaceuticals is in the top 7% for total assets. Improved from $22.7B to $25.6B over the past 2 years.
Based on SEC 10-K filings.
$25.6B in FY2025 with a 5-year CAGR of +16.9%. Top quartile in the Health Care sector.
Improved from $22.7B to $25.6B over the past 2 years.
Health Care sector context is included.
Total Assets over time
Growth rates
- 3-Year CAGR
- +12.2%
- 5-Year CAGR
- +16.9%
- 10-Year CAGR
- -
Sector benchmark
Top 7% in Health CareTop 7% of 214This company $25.6B Sector average $7.5B
▼
+243.3% above sector average
Key checks
Key Insights
- 5-year CAGR of +16.9%, indicating consistent growth.
- In FY2025, total assets increased 13.8% year-over-year.
- Ranks #15 out of 214 companies in the Health Care sector.
- Lowest total assets in the period was in FY2016.
Company context
Key Data Points
- Strong profit margin: 31.4%
- Strong return on equity: 21.2%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Total AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $25.6B | +13.8% |
| FY2024 | $22.5B | -0.9% |
| FY2023 | $22.7B | +25.2% |
| FY2022 | $18.2B | +35.1% |
| FY2021 | $13.4B | +14.3% |
| FY2020 | $11.8B | +41.3% |
| FY2019 | $8.3B | +33.2% |
| FY2018 | $6.2B | +76.1% |
| FY2017 | $3.5B | +22.4% |
| FY2016 | $2.9B | +15.9% |
As of FY2025 · SEC 10-K · Updated Mar 17, 2026